Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
…
2,368€
0,70%
Echtzeit-Aktienkurs Esperion Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Esperion Therapeutics Inc. Aktie
Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript
…
Esperion Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
…
Esperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq:…
Esperion Announces Proposed Public Offering of Common Stock
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq:…
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation…
Esperion Therapeutics, Inc. (ESPR) Q3 2023 Earnings Call Transcript
…
Esperion Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the…
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 –...…
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to…
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 8,…
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
Esperions (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday....…
Esperion Therapeutics Shares Rise 12% After 2Q Loss Narrows
Esperion Therapeutics Shares Rise 12% After 2Q Loss Narrows...…
Form 10-Q Esperion Therapeutics, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Esperion Therapeutics, For: Aug 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Reports Second Quarter 2023 Financial Results
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million –...…
Esperion Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion to Report Second Quarter 2023 Financial Results on August 1
ANN ARBOR, Mich., July 17, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second…
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a…
Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe
Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk....…
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
– Seeking inclusion of CV risk reduction indications in Europe – ...…
Form 8-K Esperion Therapeutics, For: Jun 24
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary…
Form 8-K Esperion Therapeutics, For: Jun 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists (CTT) Major Vascular Event endpoint is comparable to…
Esperion jumps 15% as BofA double-upgrades citing near-term upside
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting…
Esperion to Participate in Jefferies Healthcare Conference
ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president…
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9,…
Form 10-Q Esperion Therapeutics, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Reports First Quarter 2023 Financial Results
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million –...…
Form 8-K Esperion Therapeutics, For: May 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: General Counsel verkauft Aktien von Esperion Therapeutics im Wert von 1.641$
Looker, Benjamin - Vorstand - Tag der Transaktion: 2023-04-19...…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Esperion Therapeutics im Wert von 147$
Warren, Eric - Vorstand - Tag der Transaktion: 2023-04-19...…
Insiderhandel: Chief Medical Officer verkauft Aktien von Esperion Therapeutics im Wert von 1.192$
Foody, Joanne M. - Vorstand - Tag der Transaktion: 2023-04-19...…
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
– Performance-Based Agreement Provides for Curraxs 72 Sales Representatives to Detail Esperions Products –...…
Form 8-K Esperion Therapeutics, For: Mar 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Form 8-K Esperion Therapeutics, For: Mar 19
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Esperion Therapeutics im Wert von 937$
Warren, Eric - Vorstand - Tag der Transaktion: 2023-03-17...…
Esperion Therapeutics Shares Down 10% After $56.7 Million Offering Prices
Esperion Therapeutics Shares Down 10% After $56.7 Million Offering Prices...…
Esperion in red on pricing $56.7M in stock and short-term warrants offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the companys assessment that cardiovascular outcome CLEAR…
Why Esperion Therapeutics Stock Is Tanking Thursday
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are plummeting Thursday after the company reported a disagreement with one of its partners over…
Esperion extends selloff as Daiichi Sankyo dispute prompts BofA downgrade
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…